Vir Biotechnology, Inc. (VIR)
VIR Stock Price Chart
Explore Vir Biotechnology, Inc. interactive price chart. Choose custom timeframes to analyze VIR price movements and trends.
VIR Company Profile
Discover essential business fundamentals and corporate details for Vir Biotechnology, Inc. (VIR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Oct 2019
Employees
408.00
Website
https://www.vir.bioCEO
Marianne De Backer
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
VIR Financial Timeline
Browse a chronological timeline of Vir Biotechnology, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 30 Oct 2025
EPS estimate is -$0.70, while revenue estimate is $2.11M.
Earnings released on 6 Aug 2025
EPS came in at -$0.80 falling short of the estimated -$0.72 by -11.11%, while revenue for the quarter reached $1.21M , missing expectations by -55.40%.
Earnings released on 7 May 2025
EPS came in at -$0.88 falling short of the estimated -$0.83 by -6.02%, while revenue for the quarter reached $1.79M , missing expectations by -79.12%.
Earnings released on 26 Feb 2025
EPS came in at -$0.76 surpassing the estimated -$0.85 by +10.59%, while revenue for the quarter reached $12.37M , beating expectations by +52.01%.
Earnings released on 31 Oct 2024
EPS came in at -$1.56 falling short of the estimated -$0.96 by -62.50%, while revenue for the quarter reached $2.38M , missing expectations by -74.59%.
Earnings released on 1 Aug 2024
EPS came in at -$1.02 falling short of the estimated -$0.93 by -9.68%, while revenue for the quarter reached $3.08M , missing expectations by -59.00%.
Earnings released on 2 May 2024
EPS came in at -$0.48 surpassing the estimated -$0.99 by +51.52%, while revenue for the quarter reached $56.38M , beating expectations by +381.43%.
Earnings released on 22 Feb 2024
EPS came in at -$0.86 surpassing the estimated -$1.14 by +24.56%, while revenue for the quarter reached $16.79M , beating expectations by +25.00%.
Earnings released on 2 Nov 2023
EPS came in at -$1.22 falling short of the estimated -$1.21 by -0.83%, while revenue for the quarter reached -$4.10M , missing expectations by -140.02%.
Earnings released on 3 Aug 2023
EPS came in at -$1.45 falling short of the estimated -$1.21 by -19.83%, while revenue for the quarter reached -$12.72M , missing expectations by -149.14%.
Earnings released on 4 May 2023
EPS came in at -$1.06 falling short of the estimated -$0.81 by -30.86%, while revenue for the quarter reached $46.71M , missing expectations by -6.76%.
Earnings released on 23 Feb 2023
EPS came in at -$0.76 falling short of the estimated -$0.39 by -92.41%, while revenue for the quarter reached $21.79M , missing expectations by -85.44%.
Earnings released on 3 Nov 2022
EPS came in at $1.30 surpassing the estimated -$0.21 by +719.05%, while revenue for the quarter reached $371.43M , beating expectations by +225.20%.
Earnings released on 9 Aug 2022
EPS came in at -$0.58 falling short of the estimated -$0.17 by -241.18%, while revenue for the quarter reached -$42.69M , missing expectations by -121.27%.
Earnings released on 5 May 2022
EPS came in at $3.85 surpassing the estimated $3.78 by +1.85%, while revenue for the quarter reached $1.23B , beating expectations by +51.65%.
Earnings released on 24 Feb 2022
EPS came in at $3.92 surpassing the estimated $3.04 by +28.95%, while revenue for the quarter reached $809.76M , beating expectations by +29.99%.
Earnings released on 4 Nov 2021
EPS came in at $0.82 surpassing the estimated $0.02 by +3.49K%, while revenue for the quarter reached $102.71M , missing expectations by -2.30%.
Earnings released on 5 Aug 2021
EPS came in at $0.46 surpassing the estimated -$0.48 by +195.83%, while revenue for the quarter reached $173.99M , beating expectations by +105.75%.
Earnings released on 6 May 2021
EPS came in at -$1.32 falling short of the estimated -$0.23 by -473.91%, while revenue for the quarter reached $605.00K , missing expectations by -92.06%.
Earnings released on 25 Feb 2021
EPS came in at -$0.83 falling short of the estimated -$0.72 by -15.28%, while revenue for the quarter reached $301.00K , beating expectations by +384.04%.
Earnings released on 10 Nov 2020
EPS came in at -$0.67 falling short of the estimated -$0.57 by -17.54%, while revenue for the quarter reached $188.00K , missing expectations by -88.96%.
VIR Stock Performance
Access detailed VIR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.